2013

Coronado appoints Weisman as CEO

Wednesday, January 9, 2013

Coronado Biosciences, a Burlington, Mass.-based biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, has appointed Harlan F. Weisman, M.D., as its new chairman and CEO.

[Read More]

Shire to acquire Lotus Tissue Repair

Wednesday, January 9, 2013

Shire, a global specialty biopharmaceutical company, has signed an agreement to acquire Lotus Tissue Repair, a Cambridge, Mass.-based biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa (DEB).

[Read More]

Ambrx appoints Macartney as CEO

Tuesday, January 8, 2013

Ambrx, a clinical-stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, has appointed Lawson Macartney, Ph.D., DVM, as president and CEO of the company and a member of the board of directors.

[Read More]